ALC vs JNJ: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ALC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALC and JNJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALC and JNJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alcon makes the things an ophthalmologist and an optometrist use every day. The Surgical division sells cataract equipment (the Unity VCS and CS platforms, LenSx femtosecond lasers, the ARGOS biometer, NGENUITY 3D visualization, the Constellation vitreoretinal system) plus the intraocular lenses that get implanted during those procedures, including the PanOptix and Vivity presbyopia-correcting families and the newer Clareon TruPlus monofocal and toric lenses. The Vision Care division sells contact lenses (Precision1, Precision7, Dailies Total1, Total30) and ocular health products (Systane dry eye drops, allergy and lens care lines, and the recently launched Tryptyr dry eye drug). In the first quarter of 2026 the split was roughly $1.5 billion Surgical and $1.2 billion Vision Care on $2.7 billion of total sales, so Surgical is the larger side but not overwhelmingly so. The company is headquartered in Geneva, employs about 26,000 people, traces its roots to a 1945 Fort Worth pharmacy, and has been independent since Novartis spun it off in April 2019. It passed 175 million cumulative IOL implants in March 2026.

Full ALC guide

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALC drivers: Demographics that do not switch off; An unusually dense 2026 product cycle.
• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The immediate risk is that soft cataract and premium-lens volumes are not a 2026 phenomenon, in which case a 5% to 7% constant currency growth guide gets revised down again after multiple cuts already in 2025 and 2026. For JNJ, j&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALC if you believe its drivers more; JNJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALC and JNJ guides.

ALC. The two P/E figures tell the whole disagreement. Trailing GAAP earnings are depressed by amortization from the Novartis separation and by the cost of running several product launches at once, which is why the stock screens at roughly 50 times trailing and roughly 17 times forward. Gross margin sits near 57% and cash generation is steady, so the question is not whether the business generates cash, it is whether the 2026 margin expansion guide of 70 to 170 basis points holds through the November 10, 2026 report. Shares trade near the bottom of a ~$61.83 to ~$87.64 52-week range against an average analyst target around $83.

JNJ. J&J's trailing P/E near 39 is inflated by a third quarter in which GAAP net income fell to about $210 million on items excluded from adjusted results; on forward estimates (about $11.71 of EPS for 2027) the multiple is near 22. That is a premium to where the stock traded early in 2026, after a roughly 24% year-to-date rise, and the dividend yield has compressed to about 2.1%. The market is paying for steady mid single-digit growth, high margins, strong cash generation and a raised 2026 outlook, still with some discount for litigation and patent-cliff overhangs; figures are approximate as of October 16, 2026.

Headline figures (approximate, October 2026): ALC shows revenue (ttm) ~$10.9 billion, up ~8.7% year over year in Q2 2026, q2 2026 sales ~$2.82 billion; core diluted EPS $0.84 vs $0.76 expected, margins (ttm) ~57% gross, ~15% operating, ~6% net, earnings per share ~$1.32 trailing GAAP; ~$3.50 core expected for 2026; JNJ shows revenue (ttm) ~$99 billion, q3 2026 sales ~$25.4 billion (+~6% YoY), q3 2026 adjusted eps $2.59 (vs ~$2.52 est.), operating margin ~25%.

ALC and JNJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALC and JNJ exposure against your real portfolio. It is not an investment adviser.